Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE-RELATED DISEASE
Document Type and Number:
WIPO Patent Application WO/2018/221966
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for prevention or treatment of bone-related diseases, which promotes the differentiation of preosteoblasts into osteoblasts to induce the formation of calcified nodules and simultaneously suppresses the differentiation of myelocytes into osteoclasts and the function of osteoclasts, thereby effectively controlling bone homeostasis and being very useful for prevention or treatment of bone-related diseases. In addition, the present invention relates to a pharmaceutical composition for prevention or treatment of menopausal diseases, particularly menopausal bone diseases, wherein the pharmaceutical composition increases the volume of spongy bone and promotes the differentiation of preosteoblasts into osteoblasts to induce the formation of calcified nodules and simultaneously suppresses the differentiation of myelocytes into osteoclasts and the function of osteoclasts, thereby effectively controlling bone homeostasis and being very useful for prevention or treatment of menopausal bone-related diseases.
Inventors:
SEO JUNG TEAK (KR)
MOON SEOK JUN (KR)
KIM SUNG JIN (KR)
MOON SEOK JUN (KR)
KIM SUNG JIN (KR)
Application Number:
PCT/KR2018/006174
Publication Date:
December 06, 2018
Filing Date:
May 30, 2018
Export Citation:
Assignee:
UNIV YONSEI IACF (KR)
International Classes:
A61K31/575; A23L33/10; A61K31/18; A61K31/352; A61P15/12
Foreign References:
| KR20140018814A | 2014-02-13 | |||
| US6013642A | 2000-01-11 |
Other References:
PUROHIT, A. ET AL.: "Steroid sulfatase inhibitors for estrogen-and androgen-dependent cancers", JOURNAL OF ENDOCRINOLOGY, vol. 212, no. 2, 22 August 2011 (2011-08-22), pages 99 - 110, XP055293386, DOI: 10.1530/JOE-11-0266
FOSTER, P.A. ET AL.: "In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy", CLINICAL CANCER RESEARCH, vol. 12, no. 18, 15 September 2006 (2006-09-15), pages 5543 - 5549, XP055638218, DOI: 10.1158/1078-0432.CCR-06-0632
HANYU, O. ET AL.: "Cholesterol sulfate induces expression of the skin barrier protein filaggrin in normal human epidermal keratinocytes through induction of RORalfa", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 428, no. 1, 9 November 2012 (2012-11-09), pages 99 - 104, XP055638223, DOI: 10.1016/j.bbrc.2012.10.013
See also references of EP 3632447A4
SWARAN L., OBSTETRICS & GYNECOLOGY, vol. 91, 1998, pages 678 - 684
GREGORY R. MUNDY, JOURNAL OF BONE AND MINERAL METABOLISM, vol. 14, 1996, pages 59 - 64
CHAD DEAL, NATURE CLINICAL PRACTICE RHEUMATOLOGY, vol. 5, no. 1, 2009
KALERVOVAANANEN, ADVANCED DRUG DELIVERY REVIEWS, vol. 57, 2005, pages 959 - 971
J LIPID RES., vol. 44, no. 7, July 2003 (2003-07-01), pages 1268 - 78
"Position Statement", vol. 1113, 2015, AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS, article "Osteoporosis/Bone health in adults as a national public health priority"
SHUSTER, LYNNE T. ET AL.: "Premature menopause or early menopause: long-term health consequences", MATURITAS, vol. 65.2, 2010, pages 161 - 166
DOBBS, MATTHEW B.J JOSEPH BUCKWALTERCHARLES SALTZMAN: "Osteoporosis: the increasing role of the orthopaedist", THE IOWA ORTHOPAEDIC JOURNAL, vol. 19, 1999, pages 43
FOSTER, P.A. ET AL.: "In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy", CLINICAL CANCER RESEARCH, vol. 12, no. 18, 15 September 2006 (2006-09-15), pages 5543 - 5549, XP055638218, DOI: 10.1158/1078-0432.CCR-06-0632
HANYU, O. ET AL.: "Cholesterol sulfate induces expression of the skin barrier protein filaggrin in normal human epidermal keratinocytes through induction of RORalfa", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 428, no. 1, 9 November 2012 (2012-11-09), pages 99 - 104, XP055638223, DOI: 10.1016/j.bbrc.2012.10.013
See also references of EP 3632447A4
SWARAN L., OBSTETRICS & GYNECOLOGY, vol. 91, 1998, pages 678 - 684
GREGORY R. MUNDY, JOURNAL OF BONE AND MINERAL METABOLISM, vol. 14, 1996, pages 59 - 64
CHAD DEAL, NATURE CLINICAL PRACTICE RHEUMATOLOGY, vol. 5, no. 1, 2009
KALERVOVAANANEN, ADVANCED DRUG DELIVERY REVIEWS, vol. 57, 2005, pages 959 - 971
J LIPID RES., vol. 44, no. 7, July 2003 (2003-07-01), pages 1268 - 78
"Position Statement", vol. 1113, 2015, AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS, article "Osteoporosis/Bone health in adults as a national public health priority"
SHUSTER, LYNNE T. ET AL.: "Premature menopause or early menopause: long-term health consequences", MATURITAS, vol. 65.2, 2010, pages 161 - 166
DOBBS, MATTHEW B.J JOSEPH BUCKWALTERCHARLES SALTZMAN: "Osteoporosis: the increasing role of the orthopaedist", THE IOWA ORTHOPAEDIC JOURNAL, vol. 19, 1999, pages 43
Attorney, Agent or Firm:
LEE, Jae Young (KR)
Download PDF:
Previous Patent: SECONDARY BATTERY
Next Patent: COMPOSITION FOR POLYMERIZING HYDROGEL, HYDROGEL POLYMER DERIVED THEREFROM, AND HYDROGEL LENS COMPRIS...
Next Patent: COMPOSITION FOR POLYMERIZING HYDROGEL, HYDROGEL POLYMER DERIVED THEREFROM, AND HYDROGEL LENS COMPRIS...